Bristol-Myers Vagistat-1 introductory sales of $10 mil. recorded in second quarter.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS SQUIBB VAGISTAT-1 INTRODUCTORY SALES OF $10 MIL. were recorded from mid-May through the end of the second quarter. The one-day vaginal yeast infection treatment began shipping to stores in mid-April after it was approved by FDA on Feb. 11 ("The Tan Sheet" Feb. 17, p. 1). TV advertising for the 6.5% tioconazole OTC product began in May.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: